BioTuesdays

Author - Stephen Kilmer

Stifel starts Repare Therapeutics at buy; PT $48

Stifel launched coverage of Repare Therapeutics (NASDAQ:RPTX) with a “buy” rating and $48 price target. The stock finished at $28.48 on Sept. 22. Analyst Benjamin Burnett, Ph.D., writes that his rating is largely...

Stifel starts Kinnate Biopharma at buy; PT $32

Stifel launched coverage of Kinnate Biopharma (NASDAQ:KNTE) with a “buy” rating and $32 price target. The stock closed at $23.44 on Sept. 22. “Our positive thesis is based on the belief that the Phase 1 data for KIN...

WB cuts Eargo to market perform

William Blair downgraded Eargo (NASDAQ:EAR), a maker of hearing aids,  to “market perform” after the company’s 8K stated that an audit by the company’s largest third-party payer was being turned over to the U...

Cantor starts Annexon at OW; PT $40

Cantor Fitzgerald initiated coverage of Annexon (NASDAQ:ANNX) with an “overweight” rating and $40 price target. The stock closed at $21.12 on Sept. 22. Annexon is a platform-enabled therapeutics company focused on...

AGP starts IceCure Medical at buy; PT $14.50

Alliance Global Partners launched coverage of IceCure Medical (NASDAQ:ICCM) with a “buy” rating and price target of $14.50. The stock closed at $8.61 on Sept. 21. IceCure has developed and markets the IceCure family of...

Dermata Therapeutics Logo

Brookline starts Dermata Therapeutics at buy; PT $14

Brookline Capital Markets initiated coverage of Dermata Therapeutics (NASDAQ:DRMA) with a “buy” rating and a price target of $14. The stock closed at $4.87 on Sept. 20. Dermata is developing DMT310, a once-weekly...

Pennant Group logo

Stifel starts Pennant Group at buy; PT $37

Stifel launched coverage of Pennant Group (NASDAQ:PNTG) with a “buy” rating and price target of $37. The stock closed at $29.88 on Sept. 20. “We believe home health and hospice are the fastest-growing areas of...

Cantor starts Clarus Therapeutics at OW; PT $20

Cantor Fitzgerald initiated coverage of Clarus Therapeutics (NASDAQ:CRXT) with an “overweight” rating and $20 price target. The stock closed at $8.81 on Sept. 17. Clarus is focused on developing androgen and metabolic...